newsfilter
← Latest News
PR Newswire·

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

SUMMIT, N.J., Nov. 23, 2021 /PRNewswire/ -- The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.1 As the first-ever